Acelrx Pharmaceuticals Inc Relación de reducción
¿Qué es el Relación de reducción de Acelrx Pharmaceuticals Inc?
El Relación de reducción de Acelrx Pharmaceuticals Inc es 10.78
¿Cuál es la definición de Relación de reducción?
El ratio corto es el número de acciones vendidas en corto dividido por el volumen promedio diario.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Relación de reducción de compañías en Sector Health Care en NASDAQ en comparadas con Acelrx Pharmaceuticals Inc
¿Qué hace Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Empresas con relación de reducción similar a Acelrx Pharmaceuticals Inc
- SilverCrest Metals tiene Relación de reducción de 10.73
- Phillips 66 Partners LP tiene Relación de reducción de 10.74
- GFL Environmental tiene Relación de reducción de 10.74
- Select Medical tiene Relación de reducción de 10.74
- New Found Gold tiene Relación de reducción de 10.74
- International General Insurance Ltd tiene Relación de reducción de 10.77
- Acelrx Pharmaceuticals Inc tiene Relación de reducción de 10.78
- Anika Therapeutics tiene Relación de reducción de 10.80
- Chemtrade Logistics Income Fund tiene Relación de reducción de 10.80
- Stratus Properties tiene Relación de reducción de 10.81
- Bicycle Therapeutics plc tiene Relación de reducción de 10.82
- GoldMoney tiene Relación de reducción de 10.82
- Esperion Therapeutics tiene Relación de reducción de 10.83